Brookline Capital Acquisition filed a preliminary proxy and prospectus outlining deal terms for its proposed merger with Apexigen, a clinical-stage biopharmaceutical company.
If approved, upon closing Apexigen will continue to be led by President and CEO Xiaodong Yang, and the company expects to list on the Nasdaq under the ticker symbol APGN.
The SPAC has secured a deadline extension until November to close the deal. A vote on that extension saw 12% of the SPAC’s trust redeemed in April.
The merged enterprise was initially valued at $205 million when the deal was announced in March.
Apexigen’s wholly owned pipeline is focused on innovative antibody-based therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Read more.
